Defining optimal antithrombotic therapy post-TAVI: the contribution of ATLANTIS

Eur Heart J. 2022 Aug 1;43(29):2798-2800. doi: 10.1093/eurheartj/ehac139.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Aortic Valve Stenosis* / surgery
  • Fibrinolytic Agents / therapeutic use
  • Humans
  • Pyrazoles
  • Pyridones
  • Standard of Care
  • Transcatheter Aortic Valve Replacement*

Substances

  • Fibrinolytic Agents
  • Pyrazoles
  • Pyridones
  • apixaban